NewsDesk @bactiman63 Nirsevimab is a long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly...

NewsDesk @bactiman63 An international research team discovered the first human antibody to effectively neutralize two types of hantaviruses in animal models, according to a study published online Mar....

NewsDesk  @infectiousdiseasenews On Wednesday, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld for the pre-exposure prophylaxis of COVID-19...

By NewsDesk  @bactiman63 The State of Florida announced this week that the state now has one of the lowest COVID-19 daily average case rates in the last 7 days per 100,000 residents in the United States. “Without...

By NewsDesk  @bactiman63 Researchers this week published interim results in The New England Journal of Medicine from a Phase 3 study of the COVID-19 monoclonal antibody treatment sotrovimab, sponsored...

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab ― two monoclonal antibody treatments under Food and Drug Administration emergency use authorization...

NewsDesk @bactiman63 One dose of a new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to nine months in people who were exposed to the...

An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows. The results will inform...

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center (VUMC) to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus,...

By News Desk  @bactiman63 Biotechnology company, Ridgeback Biotherapeutics, announced recently that the U.S. Food and Drug Administration (FDA) approved EbangaTM for the treatment of Ebola. Ebanga...